Market Demand Growth DP prevalence among U.S. newborns has risen from around 5% in the 1990s to 20–30% today, creating a sizable and growing need for cranial support solutions in NICU settings. Invictus Medical’s award-winning cranial support technology positions the company to pursue hospital-level adoption and pilots that demonstrate impact on newborn outcomes and care workflows.

Targeted NICU Partnerships With a lean team, prioritize strategic partnerships with NICU leadership, hospital procurement, and neonatal clinicians. Leverage the Medical Director to drive clinical advocacy and run pilots that validate value in real-world NICU environments.

Clinical Leadership Advantage The appointment of a Medical Director signals clinical credibility; use this to engage clinical champions, develop case studies, and gather physician-led evidence to accelerate adoption and inform purchasing decisions.

Funding Growth Past investor funding and a current revenue range indicate appetite for external capital; pursue distribution partnerships and grant-supported manufacturing and regulatory efforts to scale market rollout.

Differentiation & Value Position the award-winning cranial support as a high-value solution for HAPU and DP prevention in newborns, emphasizing clinical outcomes and caregiver experience to build a compelling ROI case for hospitals and families.